# Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

> **NCT01110720** · PHASE2,PHASE3 · COMPLETED · sponsor: **Allon Therapeutics** · enrollment: 313 (actual)

## Conditions studied

- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** Davunetide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01110720
- **Lead sponsor:** Allon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2012-11
- **Final completion:** 2012-12
- **Target enrollment:** 313 (ACTUAL)
- **Last updated:** 2013-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01110720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01110720, "Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01110720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*